Introduction
The pancreas is a glandular organ with dual role in the digestive and endocrine (hormonal) systems. Because of its location and complexity within the body, it is difficult to diagnose the numerous disorders this crucial organ is subjected to, including acute and chronic pancreatitis, diabetes and cancers. Physiologically, the pancreas secretes, as an exocrine gland, digestive enzymes into a network of ducts that finally join the main pancreatic duct. These enzymes pass through the pancreatic ducts and reach the common bile duct in an inactive form. When they enter into the duodenum via the ampulla of Vater and mix with bile, they are activated.
These enzymes degrade proteins, lipids, carbohydrates and nucleic acids by the process of luminal digestion. The exocrine tissue also releases bicarbonate ions that neutralize the acidic chyme as it enters the duodenum from the stomach. As an endocrine gland, which consists of the islets of Langerhans, pancreas secretes into the bloodstream polypeptide hormones such as insulin and glucagon that play an essential role in the carbohydrate metabolism. For instance, insulin promotes the uptake of glucose by most cells, and hence, lowers plasma glucose concentration. Glucagon has metabolic effects that oppose the action of insulin. These hormones have also other effects on energy metabolism, growth and development. The insulin is generated from the proinsulin precursor molecule by the action of proteolytic enzymes, 4 which remove the central portion of the molecule (i.e. C-peptide). The endocrine tissue secretes also somatostatin, which has a wide variety of effects on the gastrointestinal function and may also inhibit insulin and glucagon secretion. In the present Chapter, I will describe in the first part the enrichment of pancreatic stem and progenitor cells from mice by means of flow cytometry fluorescence-activated cell sorting using prominin-1 as a cell surface antigen, and in the second part, the identification of 5 human CD133 + pancreatic CSC, which constitute potential targets in cancer therapy. In contrast, the existence of pancreatic stem and progenitor cells in the developing pancreas is not controversial. The pancreas develops from the posterior foregut, emerging as buds from the ventral and dorsal area of the gut tube. Although it is thought that pancreatic and duodenal homeobox 1 (Pdx1)-expressing epithelial progenitor cells give rise to endocrine, exocrine cells and duct (9) , clear evidence that isolated clonogenic pancreatic cells possess all stem cell characteristics remains to be confirmed. Transcription factor Pdx1 (also known as insulin promoter factor 1) is a master regulator of pancreas development. To get more insights into these issues, we have recently investigated the possibility to use prominin-1 as a prospective marker for the isolation and characterization of potential pancreatic stem cells.
Pancreatic Stem and Progenitor

Prominin-1 Labels Putative Pancreatic Stem and Progenitor Cells Within the Pancreas
Prominin-1 has been recognized as a cell surface antigen of hematopoietic (10) Collectively, these independent investigations suggest that prominin-1 as a cell surface antigen could be an ideal marker for the prospective isolation of stem and progenitor cells in developing pancreas and that its expression is decreased through differentiation into mature pancreatic cells notably islet cells. However, since its expression seems to persist at the apical membrane of the peripheral exocrine acini in neonatal and adult pancreas, the use of prominin-1 as a marker of pancreatic stem cells might be more restricted to the embryonic stage (14,15).
Differentiation Potential of Prominin-1 high Pancreatic Stem and Progenitor Cells in vitro
To determine whether a cell of interest harbors stem and progenitor cell properties, it is imperative to show that it contains a multilineage differentiation potential. In pancreas, for instance, we would expect that the putative stem cells could give rise to endocrine, exocrine cells and duct. Although the culture strategy (including culture conditions and growth factors)
for IPC has been intensively investigated especially in regenerative medicine for diabetes mellitus, the experimental conditions for other pancreatic cells have not been established yet.
Together with my colleagues we demonstrated that isolated prominin-1 high cells plated on stromal cells during 7 days were generating IPC clusters, but no other pancreatic cell types (14) . Indeed, other markers characteristic of endocrine tissue (e.g., glucagon, somatostatin, and pancreatic polypeptide) were detected as mRNA using a sensitive RT-PCR analysis, but contrary to insulin, not as protein by immunohistochemistry, suggesting that both i) their expression levels are very low, and ii) insulin-producing lineage is a default pathway under this culture condition (14). expressing Pdx1 in the nucleus and prominin-1 at the apical membrane were identified in the graft, which was similar to that of the embryonic pancreatic epithelium (14) . In addition, insulin and glucagon were detected within GFP + cell clusters ( Fig. 12.2A ). Specific markers of exocrine (amylase + or carboxypeptidase A + ) or ductal (Dolichos biflorous agglutinin + ) cells were also observed (Fig. 12.2B-D) . Notably, one month after engraftment, the intracellular C-peptide content in IPC increased and showed levels comparable to that in pancreatic -cells.
Prominin
Thus, most islet-like cell clusters consisted of IPC in the center and other pancreatic hormone positive cells in the periphery, including glucagon, somatostatin, and pancreatic polypeptide, which is characteristic of mature pancreatic islets (14).
Is Prominin-1 a Specific Marker of Pancreatic Stem and Progenitor Cells?
Engraftment of prominin-1 + cells resulted in the differentiation in endocrine, ductal, and exocrine cells characteristics of pancreas. However, since the issue of the heterogeneity of the prominin1 + cell population remains to be elucidated, we are not able at the moment to rule out the possibility that the different cell types detected in the graft arose from distinct progenitor cells. Even in the in vitro experiment, we did not detect colonies with evidence of progeny with mixed lineage derived from a single cell (14) . 
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There is a growing body of evidence that pancreatic stem and progenitor cells might to be located in the terminal duct. In addition, the phenomenon of "acinar-to-ductal transdifferentiation" should be taken into account. The evidence of adult rodent acinar-to-ductal transdifferentiation and conversion into IPC seems to be promising for cell replacement therapy in diabetes (21, 22) . More recently, Houbracken and colleagues demonstrated that the human acinar cell had plasticity similar to that described in rodent cells, which might be used to convert them into human IPC (23) . However, the plasticity of acinar cell to pancreatic stem and progenitor cells requires additional investigation, and it is obviously an exiting field to explore further. The current definition of CSC describes them as rare cells within a tumor that are able to self-renew and to produce the heterogeneous lineages of cancer cells (24) . The implementation of this concept explains the use of alternative terms in literature, such as "tumor-initiating cell" and "tumorigenic cell" to describe putative CSC. Moreover, CSC are often considered to be resistant to conventional treatment such as chemotherapy and radiotherapy, and treatments that fail to eliminate CSC may allow the tumor to relapse. For more details of CSC including their dynamics and the metastasis initiating cell concept, I refer the readers to an excellent review (25) . Therefore, a considerable interest in the molecular targeting and eradication of CSC is emerging for cancer therapy.
Pancreatic Cancer
As other tumors, recent reports have demonstrated that pancreatic cancer also contains a minute subpopulation of potential CSC. Li and colleagues isolated CSC from pancreatic 15 cancer using cell surface markers such as CD44, CD24, and epithelial-specific antigen (ESA) (26 showed the stem cell properties of self-renewal and the ability to produce differentiated progeny. More recently, it was reported that CD44 could be co-expressed with CD133 in pancreatic ductal adenocarcinomas raising the possibility that CD133 might be an alternative marker of human pancreatic CSC (27).
CD133 is an Alternative Marker of Human Pancreatic Cancer Stem Cells
The expression of CD133 on healthy pancreas was investigated but numerous independent research groups. As reported earlier in the mouse system (see above), Shimizu and colleagues found by means of immunohistochemistry that CD133 is expressed at the apical membrane of ductal cells in human adult pancreas (Fig. 12.3A ,B) (28), consistent with a previous report from Karbanová and colleagues (29) . Lardon and colleagues have also shown that CD133
including its widely used stem cell AC133 epitope is expressed on all duct-lining cells of human pancreas (30) . However, Shimizu and Karbanová studies did not detect CD133 expression on the epithelium of larger interlobular and main ducts (28, 29) . Indeed, CD133
expression appeared more pronounced towards the acini than larger ducts (31) . Given the expression of CD133 within the pancreas (28) (29) (30) (31) , and its detection in CSC originating from other tissues/organs (see Chapter 1), it is not excluded that particular subpopulation of CD133 + cells on the ductal epithelium might be the source of pancreatic CSC.
In diseased tissues, CD133 was concentrated in ductal metaplasia (the widespread inter-conversion of one cell type into another) of the acinar cells located in the border zone of the tumor (Fig. 12 .3C,D) (28) . Metaplasia has been associated with pancreatic cancer in both humans and animal models and a metaplasia-ductal adenocarcinoma sequence has been proposed for carcinogenesis in pancreas (32, 33) . As mentioned above, CD133 expression was also observed in ductal adenocarcinoma cells (Fig. 12.3E,F) . Remarkably, Hermann and colleagues isolated human pancreatic CSC using CD133 as a cell surface marker, and found that pancreatic CSC defined by its expression were exclusively tumorigenic and highly resistant to standard chemotherapy (34) . Moreover, in the invasive front of pancreatic cancer, double-positive CD133 and chemokine-related receptor-4 (CXCR4) cells were identified as the major metastatic CSC phenotype. Since depletion of this cell population abrogated the metastatic phenotype without affecting their tumorigenic potential, they concluded that a subpopulation of migrating CD133 + CXCR4 + CSC is essential for tumor metastasis. It is known that CXCR4 and its ligand the stromal cell derived factor-1α (SDF-1α, CXCL12) are involved in directional cell migration. A recent study has also proposed that CXCR4/SDF-1α axis plays a critical regulatory role in the genesis of human islets (35) .
In analogy to the stem cell niche, a growing body of evidence is accumulating to show that the tumor microenvironment is essential to maintain CSC. cell-like characteristics, it will be necessary to engraft a single cell and demonstrate that it reconstitutes the complex heterogeneity of a pancreatic cancer.
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In conclusion, the recent effort in the identification and characterization of pancreatic 
